Kroger posts mixed Q4 results
The retailer issued a conservative outlook for the fiscal year 2025, projecting earnings of $4.60 to $4.80 per share, below estimates. Its profit was $4.47 a share in the recently completed fiscal year.
The retailer issued a conservative outlook for the fiscal year 2025, projecting earnings of $4.60 to $4.80 per share, below estimates. Its profit was $4.47 a share in the recently completed fiscal year.
The latest move is the third pull back in two days from Trump on his tariffs.
The company's initiative follows its sponsorship of a white paper by the Med Safety Board, which found that medication errors impact one in every 30 patients.
Waterboy, a hangover hydration solution, is a hit at the Natural Products Expo West in Anaheim.
The partnership enables Medicaid, Medicare and other health insurance members to redeem benefits for healthy food and everyday health care items at Harveys Supermarket and Winn-Dixie.
Senior vice president of member programs and services Jim Whitman is retiring from the National Association of Chain Drug Stores in June.
“From working with suppliers and retailers, to handling complex supply chain issues, to knowing the needs of the membership over the course of decades, Steve defines service to a truly member-driven trade association.”
In his new role, Andersen will lead the strategic direction of the North American Pharmacy Automation Sales teams, including both Inside and Outside Sales, as well as the Clinical Consultants.
Green is leaving One Medical to become CEO of National Research Corp. (NRC Health), a provider of health-care analytics and other services, the company said.
Kuske built an impressive career in retail, beginning at Payless Drug Stores before making a lasting impact in senior merchandising management.
"This recognition is a testament to the hard work of our team, strong partnerships with our suppliers, and the trust our consumers and retail partners place in us," says Force Factor CEO.
Negotiations are in advanced stages, with both sides looking to sign the agreement as soon as Thursday — though a last-minute hurdle could still delay or derail talks, sources told the Wall Street Journal.
His commitment to CDMA led him to attend trade shows, develop new endeavors, and consistently voice his support of the association, while appreciating its fragility in a changing marketplace.
The much-anticipated biosimilars for ustekinumab, commonly known by its brand name Stelara, are set to hit the market in mid-2025.
“Terry has been a visionary and disciplined leader in making NACDS meetings and conferences the gold standard in the industry,” said NACDS president and CEO Steven Anderson.
NovoCare Pharmacy provides direct-to-patient, convenient home shipments of all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients.